[go: up one dir, main page]

BRPI0416415A - medicamento com o formato de uma pelìcula oralmente ministrável e uso de pelo menos uma substáncia ativa colinérgica atuando sobre o sistema nervoso central - Google Patents

medicamento com o formato de uma pelìcula oralmente ministrável e uso de pelo menos uma substáncia ativa colinérgica atuando sobre o sistema nervoso central

Info

Publication number
BRPI0416415A
BRPI0416415A BRPI0416415-6A BRPI0416415A BRPI0416415A BR PI0416415 A BRPI0416415 A BR PI0416415A BR PI0416415 A BRPI0416415 A BR PI0416415A BR PI0416415 A BRPI0416415 A BR PI0416415A
Authority
BR
Brazil
Prior art keywords
active substance
nervous system
central nervous
medicine
orally administered
Prior art date
Application number
BRPI0416415-6A
Other languages
English (en)
Inventor
Joachim Moormann
Hans-Rainer Hoffmann
Klaus Opitz
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of BRPI0416415A publication Critical patent/BRPI0416415A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MEDICAMENTO COM O FORMATO DE UMA PELìCULA ORALMENTE MINISTRáVEL E USO DE PELO MENOS UMA SUBSTãNCIA ATIVA COLINéRGICA ATUANDO SOBRE O SISTEMA NERVOSO CENTRAL A presente invenção refere-se a medicamentos no formato de uma película oralmente ministráveis os quais contém a substância ativa deoxipeganina e/ou um derivado de deoxipeganina e os quais podem ser usados para a ministração transmucosal das referidas substâncias ativas.
BRPI0416415-6A 2003-11-24 2004-11-08 medicamento com o formato de uma pelìcula oralmente ministrável e uso de pelo menos uma substáncia ativa colinérgica atuando sobre o sistema nervoso central BRPI0416415A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10354894A DE10354894A1 (de) 2003-11-24 2003-11-24 Orale Formulierungen des Desoxypeganins und deren Anwendungen
PCT/EP2004/012606 WO2005053698A1 (de) 2003-11-24 2004-11-08 Orale formulierungen des desoxypeganins und deren anwendungen

Publications (1)

Publication Number Publication Date
BRPI0416415A true BRPI0416415A (pt) 2007-05-08

Family

ID=34638177

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416415-6A BRPI0416415A (pt) 2003-11-24 2004-11-08 medicamento com o formato de uma pelìcula oralmente ministrável e uso de pelo menos uma substáncia ativa colinérgica atuando sobre o sistema nervoso central

Country Status (20)

Country Link
US (1) US20070155774A1 (pt)
EP (1) EP1827402A1 (pt)
JP (1) JP2007512270A (pt)
KR (1) KR20060123194A (pt)
CN (1) CN1886137A (pt)
AR (1) AR046665A1 (pt)
AU (1) AU2004294690B2 (pt)
BR (1) BRPI0416415A (pt)
CA (1) CA2546950A1 (pt)
DE (1) DE10354894A1 (pt)
EA (1) EA008945B1 (pt)
IL (1) IL175746A0 (pt)
MX (1) MXPA06005733A (pt)
MY (1) MY141008A (pt)
NO (1) NO20062668L (pt)
NZ (1) NZ547282A (pt)
TW (1) TW200526223A (pt)
UA (1) UA87291C2 (pt)
WO (1) WO2005053698A1 (pt)
ZA (1) ZA200603542B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200514579A (en) * 2003-07-24 2005-05-01 Smithkline Beecham Corp Orally dissolving films
EP1993509A2 (en) * 2006-02-17 2008-11-26 Novartis AG Disintegrable oral films
DE102006027791A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag AchE-NMDA-Kombinationswafer
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
AU2011329066B2 (en) * 2010-11-15 2017-03-09 The Ohio State University Research Foundation Controlled release mucoadhesive systems
WO2014018075A1 (en) 2012-07-23 2014-01-30 Crayola, Llc Dissolvable films and methods of using the same
DE102017127452A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag Wasserlösliche Polymerklebschichten
EP4294204A1 (en) * 2021-02-16 2023-12-27 DSM IP Assets B.V. Methods of selectively promoting animal welfare through modulation of microbiome

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN142428B (pt) * 1974-07-05 1977-07-09 Schering Ag
CH653550A5 (de) * 1981-10-20 1986-01-15 Sandoz Ag Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich.
JPS6393717A (ja) * 1986-10-09 1988-04-25 Sekisui Chem Co Ltd 口腔粘膜用粘着剤もしくは接着剤
EP0386960A3 (en) * 1989-03-07 1991-10-23 American Cyanamid Company Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
DE4018247A1 (de) * 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
DK0584185T3 (da) * 1991-05-14 2000-02-07 Ernir Snorrason Behandling af træthedssyndrom med cholinesteraseinhibitorer
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906977C1 (de) * 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
US20020151467A1 (en) * 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
DE10119863A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
DE10163667B4 (de) * 2001-12-21 2006-10-26 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen

Also Published As

Publication number Publication date
UA87291C2 (ru) 2009-07-10
ZA200603542B (en) 2007-02-28
JP2007512270A (ja) 2007-05-17
DE10354894A1 (de) 2005-07-07
CA2546950A1 (en) 2005-06-16
AR046665A1 (es) 2005-12-14
WO2005053698A1 (de) 2005-06-16
TW200526223A (en) 2005-08-16
EA200601015A1 (ru) 2006-10-27
NZ547282A (en) 2009-10-30
NO20062668L (no) 2006-06-09
US20070155774A1 (en) 2007-07-05
IL175746A0 (en) 2008-04-13
EP1827402A1 (de) 2007-09-05
MY141008A (en) 2010-02-12
KR20060123194A (ko) 2006-12-01
AU2004294690A1 (en) 2005-06-16
AU2004294690B2 (en) 2010-04-08
EA008945B1 (ru) 2007-10-26
CN1886137A (zh) 2006-12-27
MXPA06005733A (es) 2006-08-17

Similar Documents

Publication Publication Date Title
BR0307540A (pt) Preparação farmacêutica em forma de filme ou em forma de lâmina para administrar substâncias ativas, uso da preparação farmacêutica e processo para a administração oral de substância(s) farmaceuticamente ativa(s) dotadas de sabor amargo
Rathbone et al. Overview of oral mucosal delivery
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
AR025426A1 (es) Sales farmaceuticas de la sustancia activa tramadol y al menos un edulcorante, medicamentos que contienen estas sales, el uso de estas sales para lapreparacion de medicamentos y formas de administracion que contienen esas sales
SV1999000049A (es) Nuevas dihidropirimidinas 2 heterociclicamente sustituidas ref. lea 32793-sv
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
BRPI0513300A (pt) forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2-propil)-fenol
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
BRPI0518622A2 (pt) usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento
PT693924E (pt) Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
PT1256339E (pt) Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
BR0211198A (pt) Composições farmacêuticas e seu uso
ATE292453T1 (de) Antivirale arznei
CY1107295T1 (el) Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
BRPI0416415A (pt) medicamento com o formato de uma pelìcula oralmente ministrável e uso de pelo menos uma substáncia ativa colinérgica atuando sobre o sistema nervoso central
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
WO2005010022A3 (en) Agonist polypeptide of receptor for zot and zonulin
BR0109893A (pt) Preparação farmacêutica de lerisetron na forma de um sistema terapêutico transdêrmico, uso da preparação, uso da substância ativa lerisetron e método para administrar a substância ativa lerisetron a um paciente
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
BRPI0607172A2 (pt) método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR018376A1 (es) Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
DE60023285D1 (de) Gesteigerte abgabe von auf nukleinsäuren basierenden arzneimitteln

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/519, 9/00, 9/70; A61P 25/28

Ipc: A61K 31/519 (2011.01), A61K 9/00 (2011.01), A61K 9

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.